{
    "organizations": [],
    "uuid": "a0f284c13986353127cb7bf0d3565db6d957f2ea",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-sorrento-says-china-oncology-focus/brief-sorrento-says-china-oncology-focus-received-approval-in-china-to-begin-clinical-trials-for-zkab001-idUSASB0C2QM",
    "ord_in_thread": 0,
    "title": "BRIEF-Sorrento Says China Oncology Focus Received Approval In China To Begin Clinical Trials For ZKAB001",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Jan 29 (Reuters) - Sorrento Therapeutics Inc:\n* CHINA ONCOLOGY FOCUS LIMITED RECEIVES APPROVAL BY CHINESE AUTHORITIES TO BEGIN CLINICAL TRIALS IN THREE SEPARATE CANCER INDICATIONS USING SORRENTO’S ANTI-PD-L1 MONOCLONAL ANTIBODY\n* SORRENTO THERAPEUTICS - ‍CLINICAL DATA FROM STUDIES COULD BE AVAILABLE BY END OF YEAR 2019​ Source text for Eikon: Further company coverage:\n ",
    "published": "2018-01-29T21:31:00.000+02:00",
    "crawled": "2018-01-30T19:04:11.014+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "jan",
        "reuters",
        "sorrento",
        "therapeutic",
        "inc",
        "china",
        "oncology",
        "focus",
        "limited",
        "receives",
        "approval",
        "chinese",
        "authority",
        "begin",
        "clinical",
        "trial",
        "three",
        "separate",
        "cancer",
        "indication",
        "using",
        "sorrento",
        "monoclonal",
        "antibody",
        "sorrento",
        "therapeutic",
        "data",
        "study",
        "could",
        "available",
        "end",
        "year",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}